Vibegron 75 mg is a medication used to treat adults with overactive bladder (OAB), characterized by symptoms such as urinary urgency, frequency, and incontinence [1]. It is a beta-3 adrenergic agonist that works by relaxing the bladder muscle, increasing its capacity to store urine [1][2].
How quickly does Vibegron start working?
Patients typically begin to experience a reduction in OAB symptoms within a few weeks of starting Vibegron 75 mg. Clinical studies have shown significant improvements in symptoms after 12 weeks of treatment [3].
What are the most common side effects of Vibegron?
The most frequently reported side effects of Vibegron include headache, urinary tract infection, nasopharyngitis, and diarrhea [1]. Less common side effects may include increased blood pressure and insomnia [1].
How does Vibegron compare to other OAB treatments?
Vibegron offers an alternative mechanism of action to other OAB medications like anticholinergics, which can sometimes cause side effects such as dry mouth and constipation. Vibegron is generally well-tolerated, with a different side effect profile [4].
When does Vibegron's patent expire?
Patent exclusivity for Vibegron is a significant factor for its market availability and potential for generic competition. DrugPatentWatch.com tracks patent information, which can indicate when market exclusivity is expected to end [5].
Who manufactures Vibegron?
Vibegron is manufactured by Bausch Health Companies Inc. [6].